
Vol. 73, No. 1-2, 2007
Free Abstract
Article (Fulltext)
Article (PDF 442 KB)
Case Report
Treatment of Transformed Mycosis Fungoides with Intermittent Low-Dose Gemcitabine
Omar Awara, Madeleine Duvicb
aDepartment of Internal Medicine, UCLA Medical Center, Los Angeles, Calif., and bDepartment of Dermatology, MD Anderson Cancer Center, Houston, Tex., USA
Address of Corresponding Author
Oncology 2007;73:130-135 (DOI: 10.1159/000121002)
Key Words
- Lymphoma, non-Hodgkin
- Lymphoma, cutaneous T cell
- Gemcitabine
- Gemzar®
- Mycosis fungoides
- Lymphoma, large cell
Abstract
The malignant helper T cells of mycosis fungoides, a type of cutaneous T cell lymphoma, are capable of transforming into large cerebriform cells. Large cell transformation usually renders the disease more resistant to treatment and prone to relapse. Currently investigated treatment modalities for transformed mycosis fungoides are few and include phototherapy, chemotherapy, biologic response modification, targeted molecular therapy and combinations thereof. A tolerable and reliable modality has yet to be identified. Gemcitabine, a novel purine analogue, is gaining recognition as a potent agent for advanced nontransformed cutaneous T cell lymphoma. Here we present a brief review of the literature with 3 illustrative cases that additionally reveal gemcitabine monotherapy to be a practical, safe and efficacious option for mycosis fungoides that has undergone large cell transformation. Copyright © 2008 S. Karger AG, Basel
Author Contacts Omar Awar Department of Internal Medicine, UCLA Medical Center 1441 Veteran Avenue, Unit #127 Los Angeles, CA 90024 (USA) Tel. +1 409 790 1459, Fax +1 713 745 3597, E-Mail omar.awar@gmail.com
Article Information
Received: September 3, 2007
Accepted: September 3, 2007
Published online: March 13, 2008
Number of Print Pages : 6
Number of Figures : 4, Number of Tables : 0, Number of References : 30 |
|

|

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service. |
|
|